Abstract
In this chapter you will learn that tumor blood vessels play important roles in tumor progression and that targeting the tumor vasculature is an alternative cancer therapy. Blood vessels are formed by endothelial cells organized in a monolayer, attached to a basement membrane and covered by pericytes. In general, endothelial cells are adherent to each other through molecular complexes that form the adherens and tight junctions. Such adhesion complexes guarantee the barrier function of the endothelial monolayer, crucial for the regulated transport of molecules and cells between the blood and the tissue and vice-versa. Blood vessels are essential for cell survival as they bring oxygen and nutrients to cells and also participate in the transport of waste products away from tissues. In that sense, as tumors grow, through the rapid proliferation of tumor cells, they require the formation of a new vasculature that irrigates the cells. Without a new vasculature, tumor cells are too far away from a vascular bed, which results in hypoxia and nutrient starvation. These are believed to be the main triggers of new blood vessel formation. The formation of a new blood vessel from a pre-existing one is called angiogenesis and is the main type of blood vessel formation that takes place in tumors. However, other ways to ensure blood deliver to tumor cells have been described. Angiogenesis also occurs in physiological conditions such as during development and wound closure and several cellular and molecular mechanisms that govern it have been elucidated. The most common experimental models used to study physiological angiogenesis are the mouse retina, the transparent zebrafish and human endothelial cells cultured in in vitro systems. The vascular Endothelial Growth Factor (VEGF) is the main signaling molecule that regulates angiogenesis, although several other pro- and anti-angiogenic stimuli exist. In tumors, due to an imbalance of such stimuli, angiogenesis is abnormal, resulting in a disorganized and leaky vascular network. The abnormal nature of the tumor vasculature plays critical roles in cancer progression, in particular its inadequate ability to ensure the barrier function of the vessels has several pathological consequences and is an obstacle to the delivery of therapeutic drugs to tumors. Abnormally permeable blood vessels allow the uncontrolled movement of molecules, extracellular vesicles and cells, in and out of the tumor. This is the starting point for cancer to become a systemic disease. Through leaky blood vessels, tumors send signals to distant tissues, recruit and control immune response and invade the blood through a process called intravasation. Targeting blood vascular formation in tumors or its interaction with tumor and immune cells, or instead, normalize the otherwise abnormal tumor vessels, are alternatives for anti-cancer therapies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186. https://doi.org/10.1056/NEJM197111182852108
Ribatti D (2008) Judah Folkman, a pioneer in the study of angiogenesis. Angiogenesis 11:3–10. https://doi.org/10.1007/s10456-008-9092-6
Carmeliet P, Jain RK (473, 2011) Molecular mechanisms and clinical applications of angiogenesis. Nature:298–307, doi:nature10144 [pii]. https://doi.org/10.1038/nature10144
Missiaen R, Morales-Rodriguez F, Eelen G, Carmeliet P (2017) Targeting endothelial metabolism for anti-angiogenesis therapy: a pharmacological perspective. Vascul Pharmacol 90:8–18, doi:S1537-1891(16)30376-7 [pii]. https://doi.org/10.1016/j.vph.2017.01.001
Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10:417–427, doi:nrd3455 [pii]. https://doi.org/10.1038/nrd3455
Goel S et al (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91:1071–1121, doi:91/3/1071 [pii]. https://doi.org/10.1152/physrev.00038.2010
Butler JM, Kobayashi H, Rafii S (2010) Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 10:138–146, doi:nrc2791 [pii]. https://doi.org/10.1038/nrc2791
Hendry SA et al (2016) The role of the tumor vasculature in the host immune response: implications for therapeutic strategies targeting the tumor microenvironment. Front Immunol 7:621. https://doi.org/10.3389/fimmu.2016.00621
Eilken HM, Adams RH (2010) Dynamics of endothelial cell behavior in sprouting angiogenesis. Curr Opin Cell Biol 22:617–625, doi:S0955-0674(10)00133-X [pii]. https://doi.org/10.1016/j.ceb.2010.08.010
Ferrara N (2009) VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 20:158–163, doi:ecn.2009.0170 [pii]. https://doi.org/10.1684/ecn.2009.0170
Nagy JA, Dvorak AM, Dvorak HF (2007) VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2:251–275. https://doi.org/10.1146/annurev.pathol.2.010506.134925
Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306–1309
Keck PJ et al (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246:1309–1312
Senger DR et al (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983–985
Terman BI et al (1992) Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187:1579–1586, doi:0006-291X(92)90483-2 [pii]
Millauer B et al (1993) High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835–846, doi:0092-8674(93)90573-9 [pii]
Phng LK, Gerhardt H (2009) Angiogenesis: a team effort coordinated by notch. Dev Cell 16:196–208, doi:S1534-5807(09)00043-4 [pii]. https://doi.org/10.1016/j.devcel.2009.01.015
Lohela M, Bry M, Tammela T, Alitalo K (2009) VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21:154–165, doi:S0955-0674(09)00013-1 [pii]. https://doi.org/10.1016/j.ceb.2008.12.012
Tammela T, Alitalo K (2010) Lymphangiogenesis: molecular mechanisms and future promise. Cell 140:460–476, doi:S0092-8674(10)00115-7 [pii]. https://doi.org/10.1016/j.cell.2010.01.045
Tammela T et al (2008) Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454:656–660, doi:nature07083 [pii]. https://doi.org/10.1038/nature07083
Siekmann AF, Lawson ND (2007) Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries. Nature 445:781–784, doi:nature05577 [pii]. https://doi.org/10.1038/nature05577
Adams RH, Eichmann A (2010) Axon guidance molecules in vascular patterning. Cold Spring Harb Perspect Biol 2:a001875, doi:cshperspect.a001875 [pii]. https://doi.org/10.1101/cshperspect.a001875
Jones CA et al (2008) Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat Med 14:448–453, doi:nm1742 [pii]. https://doi.org/10.1038/nm1742
Koch AW et al (2011) Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B. Dev Cell 20:33–46, doi:S1534-5807(10)00551-4 [pii]. https://doi.org/10.1016/j.devcel.2010.12.001
Larrivee B et al (2007) Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis. Genes Dev 21:2433–2447, doi:21/19/2433 [pii]. https://doi.org/10.1101/gad.437807
Wang B et al (2003) Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell 4:19–29, doi:S1535610803001648 [pii]
Neufeld G, Sabag AD, Rabinovicz N, Kessler O (2012) Semaphorins in angiogenesis and tumor progression. Cold Spring Harb Perspect Med 2:a006718. https://doi.org/10.1101/cshperspect.a006718. a006718 [pii]
Pan Q et al (2007) Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11:53–67, doi:S1535-6108(06)00367-9 [pii]. https://doi.org/10.1016/j.ccr.2006.10.018
Kessler O et al (2004) Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res 64:1008–1015
Sierra JR et al (2008) Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med 205:1673–1685, doi:jem.20072602 [pii]. https://doi.org/10.1084/jem.20072602
Basile JR, Barac A, Zhu T, Guan KL, Gutkind JS (2004) Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B. Cancer Res 64:5212–5224. https://doi.org/10.1158/0008-5472.CAN-04-0126. 64/15/5212 [pii]
Pasquale EB (2008) Eph-ephrin bidirectional signaling in physiology and disease. Cell 133:38–52, doi:S0092-8674(08)00386-3 [pii]. https://doi.org/10.1016/j.cell.2008.03.011
Sawamiphak S et al (2010) Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465:487–491, doi:nature08995 [pii]. https://doi.org/10.1038/nature08995
Wang Y et al (2010) Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 465:483–486, doi:nature09002 [pii]. https://doi.org/10.1038/nature09002
Fantin A et al (2010) Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood 116:829–840, doi:blood-2009-12-257832 [pii]. https://doi.org/10.1182/blood-2009-12-257832
Lammert E, Axnick J (2012) Vascular lumen formation. Cold Spring Harb Perspect Med 2:a006619. https://doi.org/10.1101/cshperspect.a006619. a006619 [pii]
Gebala V, Collins R, Geudens I, Phng LK, Gerhardt H (2016) Blood flow drives lumen formation by inverse membrane blebbing during angiogenesis in vivo. Nat Cell Biol 18:443–450, doi:ncb3320 [pii]. https://doi.org/10.1038/ncb3320
Nicoli S et al (2010) MicroRNA-mediated integration of haemodynamics and Vegf signalling during angiogenesis. Nature 464:1196–1200, doi:nature08889 [pii]. https://doi.org/10.1038/nature08889
Gaengel K, Genove G, Armulik A, Betsholtz C (2009) Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 29:630–638, doi:ATVBAHA.107.161521 [pii]. https://doi.org/10.1161/ATVBAHA.107.161521
Augustin HG, Koh GY, Thurston G, Alitalo K (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10:165–177, doi:nrm2639 [pii]. https://doi.org/10.1038/nrm2639
Huang H, Bhat A, Woodnutt G, Lappe R (2010) Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10:575–585, doi:nrc2894 [pii]. https://doi.org/10.1038/nrc2894
Gridley T (2010) Notch signaling in the vasculature. Curr Top Dev Biol 92:277–309, doi:S0070-2153(10)92009-7 [pii]. https://doi.org/10.1016/S0070-2153(10)92009-7
Pitulescu ME, Adams RH (2010) Eph/ephrin molecules--a hub for signaling and endocytosis. Genes Dev 24:2480–2492, doi:24/22/2480 [pii]. https://doi.org/10.1101/gad.1973910
Korn C, Augustin HG (2015) Mechanisms of vessel pruning and regression. Dev Cell 34:5–17, doi:S1534-5807(15)00393-7 [pii]. https://doi.org/10.1016/j.devcel.2015.06.004
Ando J, Yamamoto K (2009) Vascular mechanobiology: endothelial cell responses to fluid shear stress. Circ J 73:1983–1992, doi:JST.JSTAGE/circj/CJ-09-0583 [pii]
Kurz H, Burri PH, Djonov VG (2003) Angiogenesis and vascular remodeling by intussusception: from form to function. News Physiol Sci 18:65–70
Lyden D et al (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194–1201. https://doi.org/10.1038/nm1101-1194. nm1101-1194 [pii]
Maniotis AJ et al (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155:739–752, doi:S0002-9440(10)65173-5 [pii]. https://doi.org/10.1016/S0002-9440(10)65173-5
Seftor RE et al (2012) Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol 181:1115–1125, doi:S0002-9440(12)00578-0 [pii]. https://doi.org/10.1016/j.ajpath.2012.07.013
Donnem T et al (2013) Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? Cancer Med 2:427–436. https://doi.org/10.1002/cam4.105
De Bock K, Cauwenberghs S, Carmeliet P (2011) Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev 21:73–79, doi:S0959-437X(10)00175-9 [pii]. https://doi.org/10.1016/j.gde.2010.10.008
Jain RK (2013) Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 31:2205–2218, doi:JCO.2012.46.3653 [pii]. https://doi.org/10.1200/JCO.2012.46.3653
Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62, doi:307/5706/58 [pii]. https://doi.org/10.1126/science.1104819
Dejana E, Tournier-Lasserve E, Weinstein BM (2009) The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev Cell 16:209–221, doi:S1534–5807(09)00032-X [pii]. https://doi.org/10.1016/j.devcel.2009.01.004
Giannotta M, Trani M, Dejana E (2013) VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity. Dev Cell 26:441–454, doi:S1534-5807(13)00507-8 [pii]. https://doi.org/10.1016/j.devcel.2013.08.020
Gavard J, Gutkind JS (2006) VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 8:1223–1234, doi:ncb1486 [pii]. https://doi.org/10.1038/ncb1486
Weis S, Cui J, Barnes L, Cheresh D (2004) Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 167:223–229, doi:jcb.200408130 [pii]. https://doi.org/10.1083/jcb.200408130
Ngok SP et al (2012) VEGF and Angiopoietin-1 exert opposing effects on cell junctions by regulating the Rho GEF Syx. J Cell Biol 199:1103–1115, doi:jcb.201207009 [pii]. https://doi.org/10.1083/jcb.201207009
Li X et al (2016) VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread. Nat Commun 7:11017, doi:ncomms11017 [pii]. https://doi.org/10.1038/ncomms11017
Reymond N, d'Agua BB, Ridley AJ (2013) Crossing the endothelial barrier during metastasis. Nat Rev Cancer 13:858–870, doi:nrc3628 [pii]. https://doi.org/10.1038/nrc3628
Deryugina EI, Quigley JP (2008) Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis. Histochem Cell Biol 130:1119–1130. https://doi.org/10.1007/s00418-008-0536-2
Stoletov K, Montel V, Lester RD, Gonias SL, Klemke R (2007) High-resolution imaging of the dynamic tumor cell vascular interface in transparent zebrafish. Proc Natl Acad Sci U S A 104:17406–17411, doi:0703446104 [pii]. https://doi.org/10.1073/pnas.0703446104
Deryugina EI, Kiosses WB (2017) Intratumoral cancer cell intravasation can occur independent of invasion into the adjacent stroma. Cell Rep 19:601–616, doi:S2211-1247(17)30425-4 [pii]. https://doi.org/10.1016/j.celrep.2017.03.064
Harney AS et al (2015) Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation simulated by TIE2hi macrophage-derived VEGFA. Cancer Discov 5:932–943, doi:2159-8290.CD-15-0012 [pii]. https://doi.org/10.1158/2159-8290.CD-15-0012
Wyckoff JB et al (2007) Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 67:2649–2656, doi:67/6/2649 [pii]. https://doi.org/10.1158/0008-5472.CAN-06-1823
Anderberg C et al (2013) Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. J Exp Med 210:563–579, doi:jem.20120662 [pii]. https://doi.org/10.1084/jem.20120662
Wieland E et al (2017) Endothelial notch1 activity facilitates metastasis. Cancer Cell 31:355–367, doi:S1535-6108(17)30007-7 [pii]. https://doi.org/10.1016/j.ccell.2017.01.007
Sonoshita M et al (2011) Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. Cancer Cell 19:125–137, doi:S1535-6108(10)00473-3 [pii]. https://doi.org/10.1016/j.ccr.2010.11.008
Zang G et al (2015) Vascular dysfunction and increased metastasis of B16F10 melanomas in Shb deficient mice as compared with their wild type counterparts. BMC Cancer 15:234. https://doi.org/10.1186/s12885-015-1269-y
Ohga N et al (2012) Heterogeneity of tumor endothelial cells: comparison between tumor endothelial cells isolated from high- and low-metastatic tumors. Am J Pathol 180:1294–1307, doi:S0002-9440(11)01107-2 [pii]. https://doi.org/10.1016/j.ajpath.2011.11.035
Maishi N et al (2016) Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysregulation of biglycan. Sci Rep 6:28039, doi:srep28039 [pii]. https://doi.org/10.1038/srep28039
Ley K, Laudanna C, Cybulsky MI, Nourshargh S (2007) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7:678–689, doi:nri2156 [pii]. https://doi.org/10.1038/nri2156
Griffioen AW et al (1998) The angiogenic factor bFGF impairs leukocyte adhesion and rolling under flow conditions. Angiogenesis 2:235–243, doi:191805 [pii]. https://doi.org/10.1023/A:1009237324501
Griffioen AW, Damen CA, Blijham GH, Groenewegen G (1996) Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 88:667–673
Zhang H, Issekutz AC (2002) Down-modulation of monocyte transendothelial migration and endothelial adhesion molecule expression by fibroblast growth factor: reversal by the anti-angiogenic agent SU6668. Am J Pathol 160:2219–2230, doi:S0002-9440(10)61169-8 [pii]. https://doi.org/10.1016/S0002-9440(10)61169-8
Dirkx AE et al (2003) Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res 63:2322–2329
Tromp SC et al (2000) Tumor angiogenesis factors reduce leukocyte adhesion in vivo. Int Immunol 12:671–676
Karikoski M et al (2014) Clever-1/stabilin-1 controls cancer growth and metastasis. Clin Cancer Res 20:6452–6464, doi:1078-0432.CCR-14-1236 [pii]. https://doi.org/10.1158/1078-0432.CCR-14-1236
Motz GT et al (2014) Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 20:607–615, doi:nm.3541 [pii]. https://doi.org/10.1038/nm.3541
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Magalhães, A., Dias, S. (2019). Angiogenesis – Vessels Recruitment by Tumor Cells. In: Fior, R., Zilhão, R. (eds) Molecular and Cell Biology of Cancer. Learning Materials in Biosciences. Springer, Cham. https://doi.org/10.1007/978-3-030-11812-9_8
Download citation
DOI: https://doi.org/10.1007/978-3-030-11812-9_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-11811-2
Online ISBN: 978-3-030-11812-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)